ETON — Recent News Coverage
All news mentioning ETON in ESEN's AI-graded feed
News stories with ETON as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on ETON. See /coverage/ETON for the 30-day aggregate.
SEEKINGALPHA.COM
·
2026-08-14
LOW
BULLISH
CORR0.42
Eton Pharmaceuticals forecasts 2026 revenue to exceed $145M while targeting adjusted EBITDA margin above 35% (NASDAQ:ETON)
$ETON
◈ ESEN AI
Eton Pharmaceuticals reported record Q2 revenue and raised full-year 2026 guidance to exceed $145M, signaling continued commercial execution momentum. The guidance increase reflects confidence in existing product portfo…
SEEKINGALPHA.COM
·
2026-08-14
LOW
NEUTRAL
CORR0.15
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
$ETON
◈ ESEN AI
This article is a transcript publication of Eton Pharmaceuticals' (ETON) Q2 2026 earnings call, a scheduled procedural disclosure rather than a market-moving catalyst. Transcript releases are routine post-earnings docum…
GLOBALNEWSWIRE
·
2026-08-05
NEUTRAL
BULLISH
CORR0.52
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
$ETON
◈ ESEN AI
Eton Pharmaceuticals (ETON) has acquired U.S. rights to ASN-001, a late-stage topical gel candidate targeting proliferating superficial infantile hemangiomas. This strategic licensing agreement from Auson Pharmaceutical…
MANILATIMES.NET
·
2026-08-03
LOW
NEUTRAL
CORR0.15
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
$ETON
◈ ESEN AI
Eton Pharmaceuticals (ETON) has scheduled release of its Q2 2026 financial results for August 13, 2026, with a management conference call at 4:30 p.m. ET. This is a routine earnings announcement from the rare disease-fo…
SEEKINGALPHA.COM
·
2026-07-22
NEUTRAL
NEUTRAL
CORR0.42
Eton Stock: Here Is How I Handle My Position With The Stock Skyrocketing (NASDAQ:ETON)
$ETON
◈ ESEN AI
Eton Pharmaceuticals (ETON) continues to execute its focused strategy of acquiring ultra-rare disease therapies, now managing a portfolio of 16 products. This acquisition-driven model has generated recent stock momentum…
EXPLORE OTHER FILTERS